Phcog.Net logo

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Article

    A Nasal Gel Formulation of Ubrogepant Nanoparticles for Enhanced and Rapid Brain Delivery in the Treatment of Migraine

    Vignesh Mohan1★, Anil Meghrajji Pethe1★ Corresponding author

    1. 1Department of Pharmaceutics, Datta Meghe College of Pharmacy, DMIHER (M), Sawangi, Wardha, Maharashtra, India.

    CORRESPONDENCE

    Vignesh Mohan

    Department of Pharmaceutics, Datta Meghe College of Pharmacy, DMIHER (M), Sawangi, Wardha, Maharashtra, India.

    vigneshmohan.orbi@gmail.com

    Received: 31-03-2025; Accepted: 10-05-2025.

    Volume 17, Issue 2 · pp. 244–252 · PUBLISHED 2026 · DOI: 10.1177/0976500X251347402

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Background: Ubrogepant is a first-generation gepant-class drug approved for the oral treatment of migraine. Objectives: This work aimed at developing an intranasal gel consisting of ubrogepant nanoparticles (NPs), with the aim of improving its therapeutic efficacy through rapid and longer action in the brain. Materials and Methods: The ubrogepant NPs were prepared using poly(lactic-co-glycolic) acid (PLGA), polyvinyl alcohol (PVA), and polysorbate 80. These NPs were then formulated into a thermo-reversible gel by using an optimized polymer, stabilizer, and process. The gel formulation was then tested by in vitro and ex vivo assays for drug release and permeation, and the pharmacodynamics and pharmacokinetics were evaluated in Sprague–Dawley rats. Results: The PLGA NPs were optimally formulated in a mucoadhesive gel, which caused significant improvement in permeability and drug retention in the nasal mucosa. The in vivo studies indicated higher concentrations of ubrogepant in the brain, with a rapid absorption compared to the intranasal NP or oral ubrogepant delivery. The rapid absorption and sustained levels in the brain were translated into significantly improved efficacy of the gel formulation in the nitroglycerin (NTG)-induced migraine model in rats. Conclusion: The optimized gel formulation of the ubrogepant NPs validated the potential of intranasal use of ubrogepant for the treatment of migraine.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Mohan, V., & Pethe, A. M. (2026). A Nasal Gel Formulation of Ubrogepant Nanoparticles for Enhanced and Rapid Brain Delivery in the Treatment of Migraine. Journal of Pharmacology and Pharmacotherapeutics, 17(2), 244–252. https://doi.org/10.1177/0976500X251347402